Its roles Owner Operator
Genentech, Inc. is a U.S.-based biotechnology company and member of the Roche Group, focused on the discovery, development, and manufacture of biologic medicines. Founded in 1976 and headquartered in South San Francisco, California, the company is known for early contributions to recombinant DNA technology and monoclonal antibody therapeutics.
Genentech’s portfolio and pipeline span oncology, immunology, neuroscience, ophthalmology, hematology, and infectious diseases. The company operates integrated R&D and cGMP biomanufacturing across multiple sites, with capabilities in large-scale mammalian cell culture, purification, and sterile fill-finish, supported by process development, analytical sciences, and quality operations. Within Roche’s global network, Genentech manages clinical and commercial supply of several biologics, including bevacizumab, trastuzumab, rituximab (with partners), atezolizumab, ocrelizumab, tocilizumab, omalizumab, and ranibizumab. The company emphasizes advanced bioprocessing, automation, and data-driven manufacturing to support reliable supply and regulatory compliance.
chemXplore tracks 3 projects involving Genentech, of which 2 are active.
Besides these 2, the record holds 1 completed project.
Closest to start-up first.
The 1 that is completed, on hold or cancelled are in the record. See all 3 in chemXplore →
Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.
FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.
evERA Phase III: giredestrant+everolimus doubled median PFS in ESR1‑mutated patients and improved ITT PFS; OS immature; manageable safety; FDA review dates set for Nov 30 and Dec 18, 2026.
Groundbreaking for a $750M, 211,000 sq ft Hillsboro expansion adds device fill-finish capacity and targets commercial operations in 2031.
Phase III interim data show significant proteinuria reduction at 37 weeks; drug targets liver-derived factor B via monthly subcutaneous dosing; blinded follow-up continues to week 105 eGFR.
Once‑weekly dual GLP‑1/GIP enicepatide cut HbA1c up to 2.65% and body weight 15.5% at 48 weeks in Phase II; safety aligned with the incretin class.
active all projects
